厌氧制备粪菌移植对溃疡性结肠炎8周缓解的影响:随机临床试验
这项多中心、随机、双盲临床试验纳入73例轻中度活动性溃疡性结肠炎成人患者,比较厌氧制备的混合供体粪菌移植(FMT)与自体FMT的疗效。
要点
- 厌氧制备供体FMT组第8周无激素缓解率为32%,显著高于自体FMT组的9%。
- 达到主要终点的12例供体FMT患者中,5例(42%)在12个月时维持缓解。
- 供体FMT组发生3例严重不良事件,自体FMT组发生2例。
核心结论
- 在轻中度活动性溃疡性结肠炎成人患者中,为期1周的厌氧制备供体FMT治疗较自体FMT可提高第8周无激素缓解的可能性。
- 需要进一步研究评估长期维持缓解和安全性。
研究设计与样本
- 多中心、随机、双盲临床试验,在3家澳大利亚三级转诊中心开展,2013年6月至2016年6月入组,随访至2017年6月。
- 共纳入73例轻中度活动性溃疡性结肠炎成人患者,随机接受厌氧制备混合供体FMT(n=38)或自体FMT(n=35),经结肠镜给药后7天内接受2次灌肠。
- 自体FMT组患者在8周时接受开放标签治疗,并随访12个月。
- 主要结局为第8周无激素缓解,定义为总Mayo评分≤2且内镜Mayo评分≤1;总Mayo评分范围0–12分。
主要发现
- 73例随机患者平均年龄39岁,女性33例(45%),69例(95%)完成试验。
- 供体FMT组达到第8周主要终点的12例中,5例(42%)在12个月时维持缓解。
- 供体FMT组发生3例严重不良事件,自体FMT组发生2例。
关键数值与推荐
- 主要结局无激素缓解定义:第8周总Mayo评分≤2且内镜Mayo评分≤1。
临床怎么用
- 对于轻中度活动性溃疡性结肠炎成人患者,可考虑短期厌氧制备供体FMT以诱导无激素缓解。
- 治疗决策需权衡严重不良事件风险,并关注长期维持缓解证据的不足。
局限性
- 研究为初步探索性试验,样本量较小(73例)。
- 长期维持缓解和安全性仍需进一步研究评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: High-intensity, aerobically prepared fecal microbiota transplantation (FMT) has demonstrated efficacy in treating active ulcerative colitis (UC). FMT protocols involving anaerobic stool processing methods may enhance microbial viability and allow efficacy with a lower treatment intensity. OBJECTIVE: To assess the efficacy of a short duration of FMT therapy to induce remission in UC using anaerobically prepared stool. DESIGN, SETTING, AND PARTICIPANTS: A total of 73 adults with mild to moderately active UC were enrolled in a multicenter, randomized, double-blind clinical trial in 3 Australian tertiary referral centers between June 2013 and June 2016, with 12-month follow-up until June 2017. INTERVENTIONS: Patients were randomized to receive either anaerobically prepared pooled donor FMT (n = 38) or autologous FMT (n = 35) via colonoscopy followed by 2 enemas over 7 days. Open-label therapy was offered to autologous FMT participants at 8 weeks and they were followed up for 12 months. MAIN OUTCOMES AND MEASURES: The primary outcome was steroid-free remission of UC, defined as a total Mayo score of ≤2 with an endoscopic Mayo score of 1 or less at week 8. Total Mayo score ranges from 0 to 12 (0 = no disease and 12 = most severe disease). Steroid-free remission of UC was reassessed at 12 months. Secondary clinical outcomes included adverse events. RESULTS: Among 73 patients who were randomized (mean age, 39 years; women, 33 [45%]), 69 (95%) completed the trial. The primary outcome was achieved in 12 of the 38 participants (32%) receiving pooled donor FMT compared with 3 of the 35 (9%) receiving autologous FMT (difference, 23% [95% CI, 4%-42%]; odds ratio, 5.0 [95% CI, 1.2-20.1]; P = .03). Five of the 12 participants (42%) who achieved the primary end point at week 8 following donor FMT maintained remission at 12 months. There were 3 serious adverse events in the donor FMT group and 2 in the autologous FMT group. CONCLUSIONS AND RELEVANCE: In this preliminary study of adults with mild to moderate UC, 1-week treatment with anaerobically prepared donor FMT compared with autologous FMT resulted in a higher likelihood of remission at 8 weeks. Further research is needed to assess longer-term maintenance of remission and safety. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12613000236796.
引用
- Costello SP, Hughes PA, Waters O, et al. Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial. JAMA. 2019. PMID: 30644982. doi:10.1001/jama.2018.20046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。